Active Ingredient History
Esketamine is an S(+)-enantiomer of ketamine. It is a nonselective, noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptor. A nasal spray, containing esketamine, was approved in 2019 for the treatment of treatment-resistant depression in adults, in conjunction with an oral antidepressant, and is marketed under tradename SPARAVATO. Esketamine is a schedule III drug product in the USA. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Depression (approved 2019)
Abortion, Induced (Phase 2)
Acute Pain (Phase 4)
Adult (Phase 4)
Analgesia (Phase 4)
Analgesia, Patient-Controlled (Phase 4)
Analgesics (Phase 4)
Anesthesia (Phase 4)
Anesthesia and Analgesia (Phase 4)
Anesthesia, Intravenous (Phase 3)
Anxiety (Phase 4)
Bipolar Disorder (Phase 4)
Brain Injuries, Traumatic (Phase 4)
Breast Neoplasms (Phase 4)
Burns (Phase 4)
Cancer Pain (Phase 2)
Carcinoma, Hepatocellular (Phase 4)
Catheters (Phase 4)
Cerebral Hemorrhage (Phase 4)
Cesarean Section (Phase 4)
Chemoembolization, Therapeutic (Phase 4)
Child (Phase 4)
Chronic Pain (Phase 4)
Cognitive Aging (Phase 4)
Conscious Sedation (Phase 4)
Critical Illness (Phase 4)
Crohn Disease (Phase 4)
Delirium (Phase 4)
Depression (Phase 4)
Depression, Postpartum (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 4)
Dexmedetomidine (Phase 4)
Drugs, Investigational (Phase 4)
Drug Therapy (Phase 4)
Electroconvulsive Therapy (Early Phase 1)
Emergency Medical Services (Phase 3)
Endometriosis (Phase 3)
Fentanyl (Phase 4)
General Surgery (Phase 4)
Geriatrics (Early Phase 1)
Healthy Volunteers (Phase 1)
Hyperalgesia (Phase 4)
Hypospadias (Phase 4)
Hysterectomy (Phase 2)
Immunosuppression Therapy (Phase 4)
Inflammation (Phase 4)
Intensive Care Units (Phase 4)
Intraoperative Complications (Phase 4)
Ketamine (Phase 4)
Kidney Failure, Chronic (Phase 1)
Laparoscopy (Phase 3)
Liver Diseases (Phase 1)
Lung Diseases (Phase 2)
Morphine (Phase 2)
Neuralgia, Postherpetic (Phase 4)
Neurosurgical Procedures (Phase 2/Phase 3)
Pain (Phase 4)
Pain, Postoperative (Phase 4)
Pediatrics (Phase 4)
Perioperative Period (Phase 4)
Postoperative Complications (Phase 4)
Pregabalin (Phase 2/Phase 3)
Pulmonary Atelectasis (Early Phase 1)
Respiration, Artificial (Phase 4)
Rhinitis, Allergic (Phase 1)
Schizophrenia (Phase 4)
Scoliosis (Phase 4)
Sepsis (Phase 4)
Sevoflurane (Phase 4)
Shock, Septic (Phase 3)
Sleep Apnea, Obstructive (Phase 4)
Sleep Quality (Phase 4)
Spinal Cord Neoplasms (Phase 2/Phase 3)
Spinal Injuries (Phase 4)
Subarachnoid Hemorrhage (Phase 4)
Substance-Related Disorders (Phase 1)
Sufentanil (Phase 4)
Thoracoscopy (Phase 4)
Tinnitus (Phase 3)
Ventilators, Mechanical (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
